Adaptive Radiotherapy Using FMISO Imaging for Head and Neck Cancer Dose Escalation Treatment with Chemotherapy in a Multicenter Study

What this Trial Is About

Researchers are evaluating adaptive radiotherapy techniques that target hypoxic areas in head and neck cancers, which are known to be resistant to radiation. The study focuses on patients with specific types of squamous cell carcinoma in the oropharynx, larynx, hypopharynx, or oral cavity, aiming to improve treatment precision by using FMISO PETCT imaging to identify these hypoxic tumor regions for dose escalation. The study compares two radiotherapy approaches a dose-escalation protocol delivering 75.9 to 79.2 Gy focused on hypoxic tumor volumes, and a standard fractionation regimen delivering 70 Gy to primary tumors and involved lymph nodes. Concurrent chemotherapy with cisplatin is given weekly or every three weeks, with total doses considered. Radiotherapy planning follows established guidelines, and treatment is delivered in 33 fractions. Patients are monitored regularly, at least every two weeks. Participants will undergo imaging assessments like CT or MRI for tumor evaluation and receive ongoing monitoring during treatment. Researchers will measure outcomes including complete response rate, locoregional progression-free survival, radiation-induced side effects, overall survival, distant metastasis-free survival, quality of life changes, and development of new hypoxic tumor areas. The study duration includes follow-ups up to four years to assess both short- and long-term effects of the treatments.

FMISO-based Adaptive Radiotherapy for Head and Neck Cancer